EOLS logo

EOLS
Evolus Inc

3,868
Mkt Cap
$428.06M
Volume
559,755.00
52W High
$10.62
52W Low
$3.86
PE Ratio
-9.69
EOLS Fundamentals
Price
$6.50
Prev Close
$6.58
Open
$6.46
50D MA
$5.06
Beta
1.12
Avg. Volume
728,672.60
EPS (Annual)
-$0.801
P/B
-14.87
Rev/Employee
$889,748.50
$529.89
Loading...
Loading...
News
all
press releases
Evolus Announces Commercial Launch of Estyme Injectable Hyaluronic Acid Gels in Europe
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme (pronounced...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Evolus Q1 Earnings Call Highlights
Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year...
MarketBeat·12d ago
News Placeholder
Evolus (EOLS) Q2 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·12d ago
News Placeholder
Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Expectations By $0.02 EPS
Evolus (NASDAQ:EOLS - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million...
MarketBeat·12d ago
News Placeholder
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended...
Business Wire·12d ago
News Placeholder
Evolus (EOLS) to Release Quarterly Earnings on Monday
Evolus (NASDAQ:EOLS) will be releasing its Q1 2026 earnings after the market closes on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-evolus-inc-stock...
MarketBeat·20d ago
News Placeholder
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by Analysts
Evolus, Inc. (NASDAQ:EOLS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommenda...
MarketBeat·26d ago
News Placeholder
Short Interest in Evolus, Inc. (NASDAQ:EOLS) Drops By 14.4%
Evolus, Inc. (NASDAQ:EOLS - Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totaling 6,517,006 shares, a decline of 14.4...
MarketBeat·29d ago
News Placeholder
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus (NASDAQ:EOLS) executives told investors at Needham & Company's 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as...
MarketBeat·1mo ago
<
1
2
...
>

Latest EOLS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.